71 results
8-K
EX-99.1
ANAB
AnaptysBio Inc
11 Mar 24
Anaptys Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
4:19pm
royalties recognized for sales of Jemperli offset by one development milestone achieved for cobolimab in 2022.
Research and development expenses were … million and $20.6 million in the same period in 2022.
Acquired in-process research and development of $7.3 million for the three and twelve months
8-K
EX-99.1
ANAB
AnaptysBio Inc
27 Nov 23
Entry into a Material Definitive Agreement
4:17pm
on developing immune cell modulators, Anaptys is well positioned to further the research and development of this program in autoimmune and inflammatory
8-K
EX-99.1
rug0ysq4oebrh5ut e6
2 Nov 23
Anaptys Announces Third Quarter 2023 Financial Results and Provides Business Update
4:18pm
8-K
EX-99.1
1tlwj8gwz2atgtug34fg
7 Aug 23
AnaptysBio Announces Second Quarter 2023 Financial Results and Provides Business Update
4:18pm
8-K
EX-99.1
nr351z
11 May 23
AnaptysBio Announces First Quarter 2023 Financial Results and Provides Pipeline Update
4:17pm
PRE 14A
itsr55fl2qmki
14 Apr 23
Preliminary proxy
4:15pm
424B5
oymp4q34k
8 Nov 22
Prospectus supplement for primary offering
4:34pm
8-K
EX-99.1
16e 68af1el3
8 Nov 22
AnaptysBio Announces Third Quarter 2022 Financial Results and Provides Pipeline Update
4:08pm
8-K
EX-99.1
9xw36vjpguygjr1 rps
8 Aug 22
AnaptysBio Announces Second Quarter 2022 Financial Results and Provides Pipeline Update
4:21pm